proportion of DRG neurons by 22% and 32% respectively; both effects were sensitive to Gi/o inhibitor pertussis toxin. Inhibitory effect of baclofen on both current types was about twice less efficacious as compared to that of the -opioid receptor agonist DAMGO. Surprisingly, only HVA but not LVA current modulation by baclofen was partially prevented by G protein inhibitor GDP--S. In contrast, only LVA but not HVA current modulation was reversed by the application of a reducing agent dithiothreitol (DTT). Inhibition of T-type Ca 2+ current by baclofen and the recovery of such inhibition by DTT were successfully reconstituted in the expression system. Our data suggest that inhibition of LVA current in DRG neurons by baclofen is partially mediated by an unconventional signaling pathway that involves a redox mechanism. These findings reinforce the idea of targeting peripheral GABA receptors for pain relief.
Introduction
Mammalian peripheral somatosensory neurons detect and transmit to CNS versatile information about body's environment; a large population of these neurons ("pain" or nociceptive neurons) responds specifically to tissue damage. Cell bodies of these neurons reside in peripheral ganglia (e.g. dorsal root ganglia, DRG) while their long, T-shaped axons form afferent sensory fibres innervating skin, muscles, joints and other bodily organs. Excitation of peripheral terminals of somatosensory fibres initiate physiological somatosensory transmission, in addition, action potentials produced elsewhere along the fibre (i.e. ectopically) can result in pathological sensations (e.g. chronic pain or 'phantom' itch) [1] . Although main somatosensory integration and processing is performed by CNS, growing evidence suggest that peripheral neurons themselves can communicate with each other, both electrically and chemically [2, 3, 4] . Accordingly, cell bodies of sensory neurons express various receptors for classical neurotransmitters such as acetylcholine, glutamate and GABA [5] . Particularly, both GABAA [6, 7, 8, 9] and GABAB [10, 11] receptors are abundantly expressed in somatosensory neurons, including nociceptors. A recent study demonstrated that peripheral nociceptive terminals are capable of releasing GABA, which acts in an autocrine fashion at the endogenous GABAB1 receptors to attenuate sensitization of heat-and inflammation-activated TRPV1 channels thus limiting hyperalgesia in rats [10] . Hence, emerging data demonstrate functional significance of peripheral GABA receptors in nociceptive neurons. Yet, the mechanisms of inhibitory action of GABAB receptors in the periphery are only beginning to emerge.
GABAB receptors belong to Gi/o type of G-protein coupled receptors (GPCR) [12] which are known to exert inhibitory action in CNS via the inhibition of voltage-gated Ca 2+ channels (VGCC) and activation of GIRK K + channels [13] . Therefore, we investigated effects of GABAB agonist baclofen on voltage-gated Ca 2+ currents in cultured small-diameter DRG neurons. DRG neurons express variety of VGCC subtypes, including high-voltage activated (HVA) N, P/Q and L-type channels [14, 15, 16, 17, 18] as well as low-voltage activated (LVA) T-type Ca 2+ channels [19, 20, 21] .
Using patch-clamp recordings we analysed effects of baclofen on both LVA and HVA currents; we found that both currents are inhibited by baclofen in subpopulations of DRG neurons. Interestingly, we found that inhibition of LVA and HVA currents was mediated by distinct mechanisms. These findings extend our understanding of GABAB receptor action in peripheral somatosensory system and suggest a possibility of targeting these receptors for analgesia.
Materials and Methods
Cell cultures and transfection. DRG neurons were cultured as described previously [22, 23, 24] . Briefly, adult Sprague Dawley rats (170 g-180 g) were humanly euthanized by isoflurane overdose. DRGs from all spinal levels were extracted and dissociated using collagenase/dispase method as described [22, 23, 24] . Dissociated cells we cultured in DMEN supplemented with GlutaMax I, 10 % fetal calf serum, penicillin (50 U/ml) and streptomycin (50 g/ml) on glass coverslips coated with poly-D-lysine for 2-5 days in a humidified incubator (37°C, 5% CO2). No growth factors were added to the culture media.
Hunan embrionic kidney cells 293 (HEK293) cells were cultured in the same DMEM supplemented with GlutaMax I, 10 % fetal calf serum, penicillin (50 U/ml) and streptomycin (50 g/ml) and passaged every 2-3 days. Human GABAB2 receptor (GenBank accession number Technologies. Baclofen, DAMGO as well as all other chemicals were from Sigma.
Statistics. All data are given as mean ± S.E.M. Differences between groups were assessed by
Student's t test (paired or unpaired, as appropriate). The differences were considered significant at P ≤ 0.05. Statistical analyses were performed using Origin 8.6 (OriginLab Corporation, Northampton, CA, USA).
Results.
In order to analyse possible effects of GABAB receptor triggering on voltage-gated Ca 2+ currents in DRG neurons we evaluated effects of baclofen (10 M) on LVA and HVA Ca 2+ currents from cultured small-diameter (soma diameter ~20 m, input resistance ~25 pA/pF) DRG neurons using whole-cell patch clamp recording. LVA and HVA currents were evoked by a double-pulse voltage protocol with a 50 ms pulse to -40 mV followed by a 100 ms pulse to 0 mV to activate LVA and HVA currents accordingly; holding potential of -90 mV was maintained throughout (Fig. 1A ).
All neurons tested displayed large HVA currents ( sensitive to the non-hydrollyzable GDP analog GDP--s, which inhibits G protein activation [25] .
Thus, inclusion of GDP--s (2 mM) into the intracellular pipette solution reduced baclofen-induced inhibition of HVA Ca 2+ currents (P < 0.05, n = 16) but had no effect on the inhibition of LVA calcium currents (P > 0.05, n = 6) (Fig. 1E, F) . This differential sensitivity of signaling cascades linking GABAB receptors with LVA and HVA Ca 2+ channels was unexpected and suggested involvement of unconventional signaling cascade in the inhibition of LVA Ca 2+ channels.
We have recently identified one such unconventional signaling cascade linking neurokinin NK1 receptors with the activation of M-type (Kv7) K + channels in DRG neurons [26] . Thus, we have shown, that acting via a PTX-sensitive mechanism, NK1 receptors stimulated release of reactive oxygen species (ROS) from mitochondria of DRG neurons and these ROS induced oxidative modification of the Kv7 channels thus potentiating their activity [26] . Indeed, Kv7 channels are highly sensitive to oxidation by ROS due to the specific cysteine pocket in the intracellular S2-S3 linker of the channel [27, 28] . Interestingly, T-type Ca 2+ channels are also sensitive to redox modulation, albeit in contrast to Kv7 channels, oxidizing compounds and ROS do not activate but inhibit T-type channel activity [21, 29, 30] . Since ROS generation by NK1 receptor triggering was sensitive to PTX [26] we hypothesized that unconventional signaling cascade causing inhibition of LVA current in DRG neurons by baclofen may also be mediated by a ROSdependent mechanism. Reducing agent DTT has been used to reverse oxidative modification of Kv7 channels [26, 27] . Therefore we tested if DTT can also reverse baclofen-induced inhibition of LVA VGCC in DRG neurons. In accordance with our hypothesis, inhibition of LVA Ca 2+ current by baclofen was partially recovered by the reducing agent DTT (1 mM). DTT recovered baclofeninhibited LVA current amplitude to 89.20 ± 2.5 % of control value ( Fig. 2A, C ; P < 0.01, n = 6),
suggesting that a part of the baclofen effect is indeed mediated by a redox mechanism. In contrast,
DTT had no effect on the inhibition of HVA Ca 2+ currents by baclofen ( Fig. 2B, D ; P > 0.05, n = 14), further supporting our finding that inhibition of LVA and HVA Ca 2+ currents by baclofen in DRG neurons is, at least in part, mediated by distinct mechanisms.
Next we tested if inhibition of LVA current by baclofen can be reconstituted in the expression system. Cav3.2 is a predominant T-type Ca 2+ channel isoform in DRG neurons [19, 20, 31, 32] . Thus, we co-expressed in HEK293 cells human GABAB2 receptors, human Cav3.2 and GFP and tested the effect of baclofen on the recombinant Cav3.2 current. Similarly to DRG neurons, baclofen (10 M) reversibly inhibited CaV3.2 currents by 24.73 ± 1.11% (Fig. 3A, B ; n = 12; P < 0.001); the inhibition was very similar in amplitude to that observed in DRG neurons (22.53 ± 2.05%).
Likewise, there was no significant effect on channel kinetics. Importantly (and similar to the effect observed in DRG neurons), the inhibition of the recombinant Cav3.2 channel currents in HEK293 cells could also be partly recovered by the reducing agent DTT (1 mM). Like in DRG neurons, DTT recovered baclofen-inhibited Cav3.2 current to 87.7 ± 0.9 % of control value ( Fig. 3C, D ; P < 0.001, n = 7). These experiments suggest that redox-mediated inhibition of T-type Ca 2+ channels by baclofen is a general property of GABAB receptors.
Finally, for comparison, we tested the effect of another prominent Gi/o-coupled receptor with analgesic properties expressed in DRG neurons, -opioid receptor (MOR) on both LVA and HVA currents. The MOR agonist DAMGO (250 nM) reversibly inhibited HVA currents in 8/9 neurons by 65.8 ± 6.7% (Fig. 4A , B, D; P < 0.001; n = 8) with an IC50 of 17.72 ± 6.9 nM (not shown). In agreement with previous study [33] , in the majority (11/14) of DRG neurons that displayed LVA current DAMGO had no effect on both LVA and HVA channels, suggesting lack of co-expression between T-type channels and MOR. Yet, in 3/14 LVA-positive neurons tested DAMGO did inhibit LVA current by 41.8 ± 10.4% ( Fig. 4A-C ; P < 0.001; n = 3). This set of experiments suggests that i)
in small sub-population of DRG neurons T-type Ca 2+ channels co-express with MOR; ii) MOR is approximately twice more efficacious in inhibiting both LVA and HVA currents in DRG neurons as compared to GABAB receptors.
Discussion
GABAB receptors are abundantly expressed in DRG neurons [11] , particularly in the cell bodies and peripheral terminals of nociceptive neurons expressing polymodal noxious sensory channel TRPV1 [10] . While at the moment there is no widely accepted theory for the potential source of GABA in the periphery, study by Hanack and colleagues suggested that nociceptive neurones themselves can produce GABA and release it at the level of peripheral terminals in response to noxious stimulation; these authors further suggested that such peripherally-released GABA acts in an autocrine way to counteract sensitization of TRPV1 channels and reduce hyperalgesia. Here we investigated additional ways by which peripheral GABAB receptors might influence nociceptive transmission. GABAB, similar to other Gi/o-coupled receptors, inhibit HVA currents using a 'fast' pathway that involves direct interaction of G protein with the channels [34, 35, 36, 37, 38] resulting in a conformational change of the channels complex that makes it harder to open by voltage [39, 40] . There are also number of other pathways by which GPCR can inhibit VGCC, including phosphatidylinositol 4,5-bisphosphate (PIP2 depletion) [41, 42] , arachidonic acid [43] and Src kinase [15] . Inhibition of T-type channels by GABAB receptors in DRG neurons has been reported [44] but the mechanism of inhibition (and particularly if it is the same as for the inhibition of HVA currents) has not been investigated. We report that in cultured small-diameter rat DRG neurons GABAB receptor agonist baclofen inhibits both HVA and LVA currents (by ~32%
and ~22% respectively) but the mechanisms of inhibition are at least partially different. In both cases inhibition was sensitive to the Gi/o inhibitor PTX, however, only the HVA current inhibition was sensitive to the non-hydrollyzable GDP analog GDP--s, which inhibits G protein activation.
In contrast, only the LVA current inhibition was sensitive to the reducing agent DTT suggesting that a non-canonical, redox-mediated mechanism contributes to the GABAB inhibition of LVA but not HVA Ca 2+ currents. Quantitatively very similar results were obtained in reconstituted system (HEK293 cells transiently overexpressing GABAB2 receptors and Cav3.2) where, again, baclofeninduced inhibition of Cav3.2 was partially recovered by DTT. Recently we have described a novel PTX-sensitive signaling cascade in nociceptive DRG neurons in which endogenous NK1 receptors produced intracellular effects by stimulating release of ROS (i.e. superoxide anion) from mitochondria. Acting as intracellular second messengers, such ROS augmented the activity of inhibitory Kv7 channels providing a mechanism for substance P mediated peripheral endogenous analgesia [26] . Because i) T-type channels are inhibited by oxidizing agents and ROS [21, 29, 30] ;
and ii) baclofen-induced inhibition of T-type channels is sensitive to DTT and PTX but not to GDP--s ( Fig. 1 & 2) , we hypothesize that similar ROS-mediated mechanism might be at play in the case of GABAB-mediated inhibition of LVA channels described here. It will be interesting to test in the future if baclofen, similar to substance P, also augments Kv7 channel activity in DRG neurons; such an effect would be predicted. Finally, our data suggest that GABAB receptor triggering produces similar (although less robust) effect on LVA and HVA currents in DRG neurons as that of MOR stimulation.
In sum, we report that GABAB receptors inhibit both HVA and LVA currents in peripheral sensory neurons albeit via distinct mechanisms. These effects reinforce the idea of targeting peripheral GABA receptors for pain relief. 
